medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2005, Number 3

<< Back Next >>

Ann Hepatol 2005; 4 (3)

Current concepts in the pathogenesis of primary biliary cirrhosis

Charatcharoenwitthaya P, Lindor KD

Language: English
References: 168
Page: 161-175
PDF size: 144.04 Kb.


Text Extraction

Primary biliary cirrhosis (PBC) is an organ-specific autoimmune disease that predominantly affects women and is characterized by chronic, progressive destruction of small intrahepatic bile duct with portal inflammation and ultimately fibrosis, leading to liver failure in the absence of treatment. The serologic hallmark of PBC is the presence of autoantibodies to mitochondria, especially to the E2 component of the pyruvate dehydrogenase complex (PDC). Current theories on the pathogenesis of PBC favor the hypothesis that the disease develops as a result of an inappropriate immune response following stimulation by an environmental or infectious agent. Like other better characterized autoimmune diseases, there appears to be a genetic susceptibility and a triggering event that initiates the autoimmune attack on bile duct cells. DRB1*0801 and DRB1*0803 are the major susceptibility alleles among Northern European and Japanese populations, respectively. The generation of immune responsiveness to self-antigen can result in pathogenic autoimmune damage of the intrahepatic biliary epithelial cells mediated by both humoral and cellular immune responses. The pathogenetic mechanism is believed to be caused by a defect in immunologic tolerance, resulting in the activation and expansion of self-antigen specific T and B lymphocyte clones and the production of circulating autoantibodies in addition to a myriad of cytokines and other inflammatory mediators. Human and animal studies have suggested that the induction of an antibody response reactive with self-antigen may result from a number of different priming events. Among the events demonstrated to induce an antibody response cross-reactive with self-PDC are exposures to bacterial PDC or retroviral proteins or xenobiotics or microchimerism. The diversity of the potential events giving rise to antibody responses cross-reactive with PDC, which could promote subsequent T-cell tolerance breakdown, suggests the intriguing possibility that PBC could represent a condition with a common final pathway but with multiple triggers able to induce a B-cell response cross-reactive with self-PDC. There are important questions about the pathogenesis of PBC which remain unanswered.


REFERENCES

  1. Kim WR, Lindor KD, Locke GR 3rd, Therneau TM, Homburger HA, Batts KP, Yawn BP, Petz JL, Melton LJ 3rd, Dickson ER. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000; 119: 1631-6.

  2. Witt-Sullivan H, Heathcote J, Cauch K, Blendis L, Ghent C, Katz A, Milner R, Pappas SC, Rankin J, Wanless IR. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 1990; 12: 98-105.

  3. Metcalf JV, Bhopal RS, Gray J, Howel D, James OF. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, England. Int J Epidemiol 1997; 26: 830-6.

  4. Balasubramaniam K, Grambsch PM, Wiesner RH, Lindor KD, Dickson ER. Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. Gastroenterology 1990; 98: 1567-71.

  5. Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994; 20: 707-13.

  6. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884-90.

  7. James SP, Hoofnagle JH, Strober W, Jones EA. NIH conference: Primary biliary cirrhosis: a model autoimmune disease. Ann Intern Med 1983; 99: 500-12.

  8. Gershwin ME. The molecular basis of primary biliary cirrhosis: interfacing clinical medicine and wet bench research. Isr J Med Sci 1995; 31: 22-30.

  9. Mackay IR, Gershwin ME. Primary biliary cirrhosis: considerations on pathogenesis based on identification of the M2 autoantigens. Springer Semin Immunopathol 1990; 12: 101-19.

  10. Jones DE, Watt FE, Metcalf JV, Bassendine MF, James OF. Familial primary biliary cirrhosis reassessed: a geographically-based population study. J Hepatol 1999; 30: 402-7.

  11. Selmi C, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish RG, Gordon SC, Wright HI, Zweiban B, Podda M, Gershwin ME. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology 2004; 127: 485-92.

  12. Watt FE, James OF, Jones DE. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM 2004; 97: 397-406.

  13. Todd JA. Genetic analysis of type 1 diabetes using whole genome approaches. Proc Natl Acad Sci U S A 1995; 92: 8560-5.

  14. Selmi C, Invernizzi P, Keeffe EB, Coppel RL, Podda M, Rossaro L, Ansari AA, Gershwin ME. Epidemiology and pathogenesis of primary biliary cirrhosis. J Clin Gastroenterol 2004; 38: 264-71.

  15. Jones DE. Fetal microchimerism: an aetiological factor in primary biliary cirrhosis? J Hepatol 2000; 33: 834-7.

  16. Rubel LR, Rabin L, Seeff LB, Licht H, Cuccherini BA. Does primary biliary cirrhosis in men differ from primary biliary cirrhosis in women? Hepatology 1984; 4(4): 671-7.

  17. Grossman CJ. Regulation of the immune system by sex steroids. Endocr Rev 1984; 5: 435-55.

  18. Ranke MB, Saenger P. Turner’s syndrome. Lancet 2001; 358: 309-14.

  19. Davis CJ, Davison RM, Payne NN, Rodeck CH, Conway GS. Female sex preponderance for idiopathic familial premature ovarian failure suggests an X chromosome defect: opinion. Hum Reprod 2000; 15: 2418-22.

  20. Invernizzi P, Miozzo M, Battezzati PM, Bianchi I, Grati FR, Simoni G, Selmi C, Watnik M, Gershwin ME, Podda M. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet 2004; 363: 533-5.

  21. Selmi C, Invernizzi P, Miozzo M, Podda M, Gershwin ME. Primary biliary cirrhosis: does X mark the spot? Autoimmun Rev 2004; 3: 493-9.

  22. Emery J, Hayflick S. The challenge of integrating genetic medicine into primary care. BMJ 2001; 322: 1027-30.

  23. Underhill J, Donaldson P, Bray G, Doherty D, Portmann B, Williams R. Susceptibility to primary biliary cirrhosis is associated with the HLA-DR8-DQB1*0402 haplotype. Hepatology 1992; 16: 1404-8.

  24. Donaldson P, Agarwal K, Craggs A, Craig W, James O, Jones D. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. Gut 2001; 48: 397-402.

  25. Begovich AB, Klitz W, Moonsamy PV, Van de Water J, Peltz G, Gershwin ME. Genes within the HLA class II region confer both predisposition and resistance to primary biliary cirrhosis. Tissue Antigens 1994; 43: 71-7.

  26. Stone J, Wade JA, Cauch-Dudek K, Ng C, Lindor KD, Heathcote EJ. Human leukocyte antigen Class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. J Hepatol 2002; 36: 8-13.

  27. Maeda T, Onishi S, Saibara T, Iwasaki S, Yamamoto Y. HLA DRw8 and primary biliary cirrhosis. Gastroenterology 1992; 103: 1118-9.

  28. Seki T, Kiyosawa K, Ota M, Furuta S, Fukushima H, Tanaka E, Yoshizawa K, Kumagai T, Mizuki N, Ando A, et al. Association of primary biliary cirrhosis with human leukocyte antigen DPB1*0501 in Japanese patients. Hepatology 1993; 18: 73-8.

  29. Oguri H, Oba S, Ogino H, et al. Association of primary biliary cirrhosis is associated with human leucocyte antigen DRB1*0803 in Japanese patients. Int Hepatol Comm 1994; 2: 263-70.

  30. Mukai T, Kimura A, Ishibashi H, et al. Association of HLA-DRB1*0803 and *1602 with susceptibility to primary biliary cirrhosis. Int Hepatol Comm 1995; 3: 207-12.

  31. Agarwal K, Jones DE, Daly AK, James OF, Vaidya B, Pearce S, Bassendine MF. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol 2000; 32: 538-41.

  32. Perrow K, Taylor JJ, James OFW, et al. Caspase 8 gene polymorphism is associated with primary biliary cirrhosis [abstract]. Hepatology 2002; 36: 417A.

  33. Graham AM, Dollinger MM, Howie SE, Harrison DJ. Identification of novel alleles at a polymorphic microsatellite repeat region in the human NRAMP1 gene promoter: analysis of allele frequencies in primary biliary cirrhosis. J Med Genet 2000; 37: 150-2.

  34. Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996; 335: 1570-1580.

  35. Bassendine MF, Jones DE, Yeaman SJ. Biochemistry and autoimmune response to the 2-oxoacid dehydrogenase complexes in primary biliary cirrhosis. Semin Liver Dis 1997; 17: 49-60.

  36. Yeaman SJ, Kirby JA, Jones DE. Autoreactive responses to pyruvate dehydrogenase complex in the pathogenesis of primary biliary cirrhosis. Immunol Rev 2000; 174: 238-49.

  37. De Marcucci O, Lindsay JG. Component X. An immunologically distinct polypeptide associated with mammalian pyruvate dehydrogenase multi-enzyme complex. Eur J Biochem 1985; 149: 641-8.

  38. Coppel RL, McNeilage LJ, Surh CD, Van de Water J, Spithill TW, Whittingham S, Gershwin ME. Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: dihydrolipoamide acetyltransferase. Proc Natl Acad Sci U S A 1988; 85: 7317-21.

  39. Fregeau DR, Roche TE, Davis PA, Coppel R, Gershwin ME. Primary biliary cirrhosis. Inhibition of pyruvate dehydrogenase complex activity by autoantibodies specific for E1 alpha, a non-lipoic acid containing mitochondrial enzyme. J Immunol 1990; 144: 1671-6.

  40. Fussey SP, Guest JR, James OF, Bassendine MF, Yeaman SJ. Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc Natl Acad Sci U S A 1988; 85: 8654-8.

  41. Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987; 138: 3525-31.

  42. Surh CD, Roche TE, Danner DJ, Ansari A, Coppel RL, Prindiville T, Dickson ER, Gershwin ME. Antimitochondrial autoantibodies in primary biliary cirrhosis recognize cross-reactive epitope(s) on protein X and dihydrolipoamide acetyltransferase of pyruvate dehydrogenase complex. Hepatology 1989; 10: 127-33.

  43. Van de Water J, Gershwin ME, Leung P, Ansari A, Coppel RL. The autoepitope of the 74-kD mitochondrial autoantigen of primary biliary cirrhosis corresponds to the functional site of dihydrolipoamide acetyltransferase. J Exp Med 1988; 167: 1791-9.

  44. Yeaman SJ, Fussey SP, Danner DJ, James OF, Mutimer DJ, Bassendine MF. Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet 1988; 1: 1067-70.

  45. Van de Water J, Fregeau D, Davis P, Ansari A, Danner D, Leung P, Coppel R, Gershwin ME. Autoantibodies of primary biliary cirrhosis recognize dihydrolipoamide acetyltransferase and inhibit enzyme function. J Immunol 1988; 141: 2321-4.

  46. Palmer JM, Jones DE, Quinn J, McHugh A, Yeaman SJ. Characterization of the autoantibody responses to recombinant E3 binding protein (protein X) of pyruvate dehydrogenase in primary biliary cirrhosis. Hepatology 1999; 30: 21-6.

  47. Quinn J, Diamond AG, Palmer JM, Bassendine MF, James OF, Yeaman SJ. Lipoylated and unlipoylated domains of human PDC-E2 as autoantigens in primary biliary cirrhosis: significance of lipoate attachment. Hepatology 1993; 18: 1384-91.

  48. Leung PS, Quan C, Park O, Van de Water J, Kurth MJ, Nantz MH, Ansari AA, Coppel RL, Lam KS, Gershwin ME. Immunization with a xenobiotic 6-bromohexanoate bovine serum albumin conjugate induces antimitochondrial antibodies. J Immunol 2003; 170: 5326-32.

  49. Palmer JM, Robe AJ, Burt AD, Kirby JA, Jones DE. Covalent modification as a mechanism for the breakdown of immune tolerance to pyruvate dehydrogenase complex in the mouse. Hepatology 2004; 39: 1583-92.

  50. Courvalin JC, Worman HJ. Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis 1997; 17: 79-90.

  51. Szostecki C, Guldner HH, Will H. Autoantibodies against “nuclear dots” in primary biliary cirrhosis. Semin Liver Dis 1997; 17: 71-8.

  52. Invernizzi P, Podda M, Battezzati PM, Crosignani A, Zuin M, Hitchman E, Maggioni M, Meroni PL, Penner E, Wesierska-Gadek J. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 2001; 34: 366-72.

  53. Bandin O, Courvalin JC, Poupon R, Dubel L, Homberg JC, Johanet C. Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology 1996; 23: 1020-4.

  54. Wesierska-Gadek J, Hohenauer H, Hitchman E, Penner E. Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. Gastroenterology 1996; 110: 840-7.

  55. Zuchner D, Sternsdorf T, Szostecki C, Heathcote EJ, Cauch-Dudek K, Will H. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology 1997; 26: 1123-30.

  56. Yang WH, Yu JH, Nakajima A, Neuberg D, Lindor K, Bloch DB. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin Gastroenterol Hepatol 2004; 2: 1116-22.

  57. Akisawa N, Nishimori I, Miyaji E, Iwasaki S, Maeda T, Shimizu H, Sato N, Onishi S. The ability of anti-carbonic anhydrase II antibody to distinguish autoimmune cholangitis from primary biliary cirrhosis in Japanese patients. J Gastroenterol 1999; 34: 366-71.

  58. Comay D, Cauch-Dudek K, Hemphill D, Diamandis E, Wanless I, Heathcote EJ. Are antibodies to carbonic anhydrase II specific for anti-mitochondrial antibody-negative primary biliary cirrhosis? Dig Dis Sci 2000; 45: 2018-21.

  59. Invernizzi P, Battezzati PM, Crosignani A, Zermiani P, Bignotto M, Del Papa N, Zuin M, Podda M. Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status. Clin Exp Immunol 1998; 114: 448-54.

  60. Akisawa N, Maeda T, Iwasaki S, Onishi S. Identification of an autoantibody against alpha-enolase in primary biliary cirrhosis. J Hepatol 1997; 26: 845-51.

  61. Muratori L, Muratori P, Zauli D, Grassi A, Pappas G, Rodrigo L, Cassani F, Lenzi M, Bianchi FB. Antilactoferrin antibodies in autoimmune liver disease. Clin Exp Immunol 2001; 124: 470-3.

  62. Panzer S, Penner E, Nelson PJ, Prochazka E, Benda H, Saurugger PN. Identification of the platelet glycoprotein IIb/IIIa complex as a target antigen in primary biliary cirrhosis-associated autoimmune thrombocytopenia. Evidence that platelet-reactive autoantibodies can also bind to the mitochondrial antigen M2. J Autoimmun 1990; 3: 473-83.

  63. Wies I, Brunner S, Henninger J, Herkel J, Kanzler S, Meyer zum Buschenfelde KH, Lohse AW. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000; 355: 1510-5.

  64. Fida S, Myers MA, Whittingham S, Rowley MJ, Ozaki S, Mackay IR. Autoantibodies to the transcriptional factor SOX13 in primary biliary cirrhosis compared with other diseases. J Autoimmun 2002; 19: 251-7.

  65. Migliaccio C, Nishio A, Van de Water J, Ansari AA, Leung PS, Nakanuma Y, Coppel RL, Gershwin ME. Monoclonal antibodies to mitochondrial E2 components define autoepitopes in primary biliary cirrhosis. J Immunol 1998; 161: 5157-63.

  66. Tsuneyama K, Van de Water J, Leung PS, Cha S, Nakanuma Y, Kaplan M, De Lellis R, Coppel R, Ansari A, Gershwin ME. Abnormal expression of the E2 component of the pyruvate dehydrogenase complex on the luminal surface of biliary epithelium occurs before major histocompatibility complex class II and BB1/B7 expression. Hepatology 1995; 21: 1031-7.

  67. Harada K, Van de Water J, Leung PS, Coppel RL, Nakanuma Y, Gershwin ME. In situ nucleic acid hybridization of pyruvate dehydrogenase complex-E2 in primary biliary cirrhosis: pyruvate dehydrogenase complex-E2 messenger RNA is expressed in hepatocytes but not in biliary epithelium. Hepatology 1997; 25: 27-32.

  68. Odin JA, Huebert RC, Casciola-Rosen L, LaRusso NF, Rosen A. Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. J Clin Invest 2001; 108: 223-32.

  69. Matsumura S, Van De Water J, Kita H, Coppel RL, Tsuji T, Yamamoto K, Ansari AA, Gershwin ME. Contribution to antimitochondrial antibody production: cleavage of pyruvate dehydrogenase complex-E2 by apoptosis-related proteases. Hepatology 2002; 35: 14-22.

  70. Strater J, Moller P. Pathogenesis of primary biliary cirrhosis: CD95-induced apoptosis at last? Eur J Gastroenterol Hepatol 1998; 10: 539-41.

  71. Kuroki T, Seki S, Kawakita N, Nakatani K, Hisa T, Kitada T, Sakaguchi H. Expression of antigens related to apoptosis and cell proliferation in chronic nonsuppurative destructive cholangitis in primary biliary cirrhosis. Virchows Arch 1996; 429: 119-29.

  72. Koga H, Sakisaka S, Ohishi M, Sata M, Tanikawa K. Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology 1997; 25: 1077-84.

  73. Graham AM, Dollinger MM, Howie SE, Harrison DJ. Bile duct cells in primary biliary cirrhosis are ‘primed’ for apoptosis. Eur J Gastroenterol Hepatol 1998; 10: 553-7.

  74. Tinmouth J, Lee M, Wanless IR, Tsui FW, Inman R, Heathcote EJ. Apoptosis of biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. Liver 2002; 22: 228-34.

  75. Iwata M, Harada K, Kono N, Kaneko S, Kobayashi K, Nakanuma Y. Expression of Bcl-2 familial proteins is reduced in small bile duct lesions of primary biliary cirrhosis. Hum Pathol 2000; 31: 179-84.

  76. Macdonald P, Palmer J, Kirby JA, Jones DE. Apoptosis as a mechanism for cell surface expression of the autoantigen pyruvate dehydrogenase complex. Clin Exp Immunol 2004; 136: 559-67.

  77. Palmer JM, Kirby JA, Jones DE. The immunology of primary biliary cirrhosis: the end of the beginning? Clin Exp Immunol 2002; 129: 191-7.

  78. Klein R, Wiebel M, Engelhart S, Berg PA. Sera from patients with tuberculosis recognize the M2a-epitope (E2-subunit of pyruvate dehydrogenase) specific for primary biliary cirrhosis. Clin Exp Immunol 1993; 92: 308-16.

  79. Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001; 33: 22-7.

  80. Friberg H, Ferrand-Drake M, Bengtsson F, Halestrap AP, Wieloch T. Cyclosporin A, but not FK 506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death. J Neurosci 1998; 18: 5151-9.

  81. Migliaccio C, Nishio A, Van de Water J, Ansari AA, Leung PS, Nakanuma Y, Coppel RL, Gershwin ME. Monoclonal antibodies to mitochondrial E2 components define autoepitopes in primary biliary cirrhosis. J Immunol 1998; 161: 5157-63.

  82. Van de Water J, Turchany J, Leung PS, Lake J, Munoz S, Surh CD, Coppel R, Ansari A, Nakanuma Y, Gershwin ME. Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2. J Clin Invest 1993; 91: 2653-64.

  83. Nishio A, Van de Water J, Leung PS, Joplin R, Neuberger JM, Lake J, Bjorkland A, Totterman TH, Peters M, Worman HJ, Ansari AA, Coppel RL, Gershwin ME. Comparative studies of antimitochondrial autoantibodies in sera and bile in primary biliary cirrhosis. Hepatology 1997; 25: 1085-9.

  84. Brown WR, Kloppel TM. The liver and IgA: immunological, cell biological and clinical implications. Hepatology 1989; 9: 763-84.

  85. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86-9.

  86. Meuer SC, Moebius U, Manns MM, Dienes HP, Ramadori G, Hess G, Hercend T, Meyer zum Buschenfelde KH. Clonal analysis of human T lymphocytes infiltrating the liver in chronic active hepatitis B and primary biliary cirrhosis. Eur J Immunol 1988; 18: 1447-52.

  87. Van de Water J, Ansari AA, Surh CD, Coppel R, Roche T, Bonkovsky H, Kaplan M, Gershwin ME. Evidence for the targeting by 2-oxo-dehydrogenase enzymes in the T cell response of primary biliary cirrhosis. J Immunol 1991; 146: 89-94.

  88. Van de Water J, Ansari A, Prindiville T, Coppel RL, Ricalton N, Kotzin BL, Liu S, Roche TE, Krams SM, Munoz S, Gershwin ME. Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis. J Exp Med 1995; 181: 723-33.

  89. Jones DE, Palmer JM, James OF, Yeaman SJ, Bassendine MF, Diamond AG. T-cell responses to the components of pyruvate dehydrogenase complex in primary biliary cirrhosis. Hepatology 1995; 21: 995-1002.

  90. Shimoda S, Nakamura M, Ishibashi H, Hayashida K, Niho Y. HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med 1995; 181: 1835-45.

  91. Kita H, Imawari M, Gershwin ME. Cellular immune response in primary biliary cirrhosis. Hepatol Res 2004; 28:12-17.

  92. Shimoda S, Van de Water J, Ansari A, Nakamura M, Ishibashi H, Coppel RL, Lake J, Keeffe EB, Roche TE, Gershwin ME. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest 1998; 102: 1831-40.

  93. Wong FS, Karttunen J, Dumont C, Wen L, Visintin I, Pilip IM, Shastri N, Pamer EG, Janeway CA Jr. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat Med 1999; 5: 1026-31.

  94. Chou YK, Bourdette DN, Offner H, Whitham R, Wang RY, Hashim GA, Vandenbark AA. Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. J Neuroimmunol 1992; 38: 105-13.

  95. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994; 179: 973-84.

  96. Link H, Sun JB, Wang Z, Xu Z, Love A, Fredrikson S, Olsson T. Virus-reactive and autoreactive T cells are accumulated in cerebrospinal fluid in multiple sclerosis. J Neuroimmunol 1992; 38: 63-73.

  97. Kita H, Lian ZX, Van de Water J, He XS, Matsumura S, Kaplan M, Luketic V, Coppel RL, Ansari AA, Gershwin ME. Identification of HLA-A2-restricted CD8 (+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J Exp Med 2002; 195: 113-23.

  98. Kita H, Matsumura S, He XS, Ansari AA, Lian ZX, Van de Water J, Coppel RL, Kaplan MM, Gershwin ME. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest 2002; 109: 1231-40.

  99. Kita H, Naidenko OV, Kronenberg M, Ansari AA, Rogers P, He XS, Koning F, Mikayama T, Van De Water J, Coppel RL, Kaplan M, Gershwin ME. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 2002; 123: 1031-43.

  100. Sadamoto T, Joplin R, Keogh A, Mason A, Carman W, Neuberger J. Expression of pyruvate-dehydrogenase complex PDC-E2 on biliary epithelial cells induced by lymph nodes from primary biliary cirrhosis. Lancet 1998; 352: 1595-6.

  101. Keogh A, Sadamoto T, Joplin R, Carman W, Mason AL, Xu L, et al. Expression of pyruvate-dehydrogenase complex PDC-E2 on biliary epithelial cells induced by incubation lymph nodes from primary biliary cirrhosis. Hepatology 1999; 30: 147A.

  102. Mason AL, Xu L, Guo L, Garry RF. Retroviruses in autoimmune liver disease: genetic or environmental agents? Arch Immunol Ther Exp 1999; 47: 289-97.

  103. Perron H, Seigneurin JM. Human retroviral sequences associated with extracellular particles in autoimmune diseases: epiphenomenon or possible role in aetiopathogenesis? Microbes Infect 1999; 1: 309-22.

  104. De Boer EC, Teppema JS, Steerenberg PA, De Jong WH. Retrovirus type C in the mouse bladder carcinoma cell line MBT-2. J Urol 2000; 163: 1999-2001.

  105. Popovic M, Kalyanaraman VS, Reitz MS, Sarngadharan MG. Identification of the RPMI 8226 retrovirus and its dissemination as a significant contaminant of some widely used human and marmoset cell lines. Int J Cancer 1982; 30: 93-9.

  106. Leung PS, Chuang DT, Wynn RM, Cha S, Danner DJ, Ansari A, Coppel RL, Gershwin ME. Autoantibodies to BCOADC-E2 in patients with primary biliary cirrhosis recognize a conformational epitope. Hepatology 1995; 22: 505-13.

  107. Krams SM, Surh CD, Coppel RL, Ansari A, Ruebner B, Gershwin ME. Immunization of experimental animals with dihydrolipoamide acetyltransferase, as a purified recombinant polypeptide, generates mitochondrial antibodies but not primary biliary cirrhosis. Hepatology 1989; 9: 411-6.

  108. Jones DE, Palmer JM, Kirby JA, De Cruz DJ, McCaughan GW, Sedgwick JD, Yeaman SJ, Burt AD, Bassendine MF. Experimental autoimmune cholangitis: a mouse model of immune-mediated cholangiopathy. Liver 2000; 20: 351-6.

  109. Joshi S, Cauch-Dudek K, Heathcote EJ, Lindor K, Jorgensen R, Klein R. Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis? Am J Gastroenterol 2002; 97: 999-1002.

  110. Martinez OM, Villanueva JC, Gershwin ME, Krams SM. Cytokine patterns and cytotoxic mediators in primary biliary cirrhosis. Hepatology 1995; 21: 113-9.

  111. Charlton B, Lafferty KJ. The Th1/Th2 balance in autoimmunity. Curr Opin Immunol 1995; 7: 793-8.

  112. Krams SM, Cao S, Hayashi M, Villanueva JC, Martinez OM. Elevations in IFN-gamma, IL-5 and IL-10 in patientswith the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30. Clin Immunol Immunopathol 1996; 80: 311-320.

  113. Neuman M, Angulo P, Malkiewicz I, Jorgensen R, Shear N, Dickson ER, Haber J, Katz G, Lindor K. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol 2002; 17: 196-202.

  114. Penners E, Goldenberg H, Albini B, Weiser MM, Milgrom F. Immune complexes in primary biliary cirrhosis contain mitochondrial antigens. Clin Immunol Immunopathol 1982; 22: 394-9.

  115. Manns MP, Bremm A, Schneider PM, Notghi A, Gerken G, Prager-Eberle M, Stradmann-Bellinghausen B, Meyer zum Buschenfelde KH, Rittner C. HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis. Gastroenterology 1991; 101: 1367-73.

  116. Potter BJ, Elias E, Thomas HC, Sherlock S. Complement metabolism in chronic liver disease: catabolism of C1q in chronic active liver disease and primary biliary cirrhosis. Gastroenterology 1980; 78: 1034-40.

  117. James SP, Elson CO, Jones EA, Strober W. Abnormal regulation of immunoglobulin synthesis in vitro in primary biliary cirrhosis. Gastroenterology 1980; 79: 242-54.

  118. Lohse AW, Reckmann A, Kyriatsoulis A, Gerken G, Meyer zum Buschenfelde KH, Manns M. In vitro secretion of specific antimitochondrial antibodies in primary biliary cirrhosis. J Hepatol 1992; 16: 165-70.

  119. Ljubuncic P, Fuhrman B, Oiknine J, Aviram M, Bomzon A. Effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxidation in cultured macrophages. Gut 1996; 39: 475-8.

  120. Britton RS, Brown KE. Genetic hemochromatosis and Wilson’s disease: role for oxidant stress? Hepatology 1995; 21: 1195-7.

  121. Sokol RJ, Winklhofer-Roob BM, Devereaux MW, McKim JM Jr. Generation of hydroperoxides in isolated rat hepatocytes and hepatic mitochondria exposed to hydrophobic bile acids. Gastroenterology 1995; 109: 1249-56.

  122. Paradis V, Kollinger M, Fabre M, Holstege A, Poynard T, Bedossa P. In situ detection of lipid peroxidation by-products in chronic liver diseases. Hepatology 1997; 26: 135-42.

  123. Kawamura K, Kobayashi Y, Kageyama F, Kawasaki T, Nagasawa M, Toyokuni S, Uchida K, Nakamura H. Enhanced hepatic lipid peroxidation in patients with primary biliary cirrhosis. Am J Gastroenterol 2000; 95: 3596-601.

  124. Ono M, Sekiya C, Ohhira M, Ohhira M, Namiki M, Endo Y, Suzuki K, Matsuda Y, Taniguchi N. Elevated level of serum Mn-superoxide dismutase in patients with primary biliary cirrhosis: possible involvement of free radicals in the pathogenesis in primary biliary cirrhosis. J Lab Clin Med 1991; 118: 476-83.

  125. Pemberton PW, Aboutwerat A, Smith A, Burrows PC, McMahon RF, Warnes TW. Oxidant stress in type I autoimmune hepatitis: the link between necroinflammation and fibrogenesis? Biochim Biophys Acta 2004; 1689: 182-9.

  126. Battista S, Bar F, Mengozzi G, Pollet C, Torchio M, Cavalli G, Rosina F, et al. Evidence of an increased nitric oxide production in primary biliary cirrhosis. Am J Gastroenterol 2001; 96: 869-875.

  127. Hokari A, Zeniya M, Esumi H, Kawabe T, Gershwin ME, Toda G. Detection of serum nitrite and nitrate in primary biliary cirrhosis: possible role of nitric oxide in bile duct injury. J Gastroenterol Hepatol 2002; 17: 308-315.

  128. Wu CT, Eiserich JP, Ansari AA, Coppel RL, Balasubramanian S, Bowlus CL, Gershwin ME, Van De Water J. Myeloperoxidase-positive inflammatory cells participate in bile duct damage in primary biliary cirrhosis through nitric oxide-mediated reactions. Hepatology 2003; 38: 1018-25.

  129. Parola M, Pinzani M, Casini A, Albano E, Poli G, Gentilini A, Gentilini P, Dianzani MU. Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen alpha 1 (I) gene expression in human liver fat-storing cells. Biochem Biophys Res Commun 1993; 194: 1044-50.

  130. Harada K, Ozaki S, Gershwin ME, Nakanuma Y. Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis. Hepatology 1997; 26: 1399-1405

  131. Jones DEJ, Palmer JM, Bennett K, Robe AJ, Yeaman SJ, Robertson H, et al. Investigation of a mechanism for accelerated breakdown of immune-tolerance to the primary biliary cirrhosis associated autoantigen, pyruvate dehydrogenase complex. Lab Invest 2002; 82: 211-219.

  132. Robe AJ, Kirby JA, Jones DE, Palmer JM. A key role for autoreactive B cells in the breakdown of T-cell tolerance to pyruvate dehydrogenase complex in the mouse. Hepatology 2005; 41: 1106-12.

  133. Mamula MJ, Janeway CA. Do B cells drive the diversification of immune responses? Immunol Today 1993; 14: 151-152.

  134. Constant SL. B lymphocytes as antigen-presenting cells for CD4+ T-cell priming in vivo. J Immunol 1999; 162: 5696-5703.

  135. Fuchs E, Matzinger P. B cells drive diversification but not directly. Immunol Today 1993; 14: 153-154.

  136. Butler P, Hamilton-Miller J, Baum H, Burroughs AK. Detection of M2 antibodies in patients with recurrent urinary tract infection using an ELISA and purified PBC specific antigens. Evidence for a molecular mimicry mechanism in the pathogenesis of primary biliary cirrhosis. Biochem Mol Biol Int 1995; 35: 473-485.

  137. Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 2001; 21: 225-232.

  138. Xu L, Shen S, Guo L, Fodera B, Keogh A, Joplin R, et al. Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci U S A 2003; 100: 8454-8459.

  139. Jones DE. Fetal microchimerism: an aetiological factor in primary biliary cirrhosis? J Hepatol 2000; 33: 834-7.

  140. Potter KN, Thomson RK, Hamblin A, Richards SD, Lindsay JG, Stevenson FK. Immunogenetic analysis reveals that epitope shifting occurs during B-cell affinity maturation in primary biliary cirrhosis. J Molec Biol 2001; 306: 37-46.

  141. Burroughs AK, Rosenstein IJ, Epstein O, Hamilton-Miller JM, Brumfitt W, Sherlock S. Bacteriuria and primary biliary cirrhosis. Gut 1984; 25: 133-7.

  142. Butler P, Valle F, Hamilton-Miller JM, Brumfitt W, Baum H, Burroughs AK. M2 mitochondrial antbodies and urinary rough mutant bacteris in patients with primary biliary cirrhosis and in patients with recurrent bacteriuria. J Hepatol 1993; 17: 408-14.

  143. Mayo I, Arizti P, Pares A, Oliva J, Doforno RA, De Sagarra MR, Rodes J, Castano JG. Antibodies against the COOH-terminal region of E. coli C1pP protease in patients with primary biliary cirrhosis. J Hepatol 2000; 33: 528-36.

  144. Tsuneyama K, Harada K, Kono Net al. Scavenger cells with gram-positive bacterial lipoteichoic acid infiltrate around the damaged interlobular bile ducts of primary biliary cirrhosis. J Hepatol 2001; 35: 156-63.

  145. Tsuneyama K, Harada K, Yasoshima M, Hiramatsu K, Mackay CR, Mackay IR, Gershwin ME, Nakanuma Y. Monocyte chemotactic protein-1, -2, and -3 are distinctively expressed in portal tracts and granulomata in primary biliary cirrhosis: Implications foe pathogenesis. J Pathol 2001; 193: 102-9.

  146. Fussey SP, Ali ST, James OF, et al. Reactivity of primary biliary cirrhosis sera with Escherichia coli dihydrolipoamide acetlytransferase (E2p): Characterization of the main immunogenic region. Proc Natl Acad Sci USA 1990; 87: 3987-91.

  147. Bogdanos DP, Grasso A, Okamoto M, Montalto P, Butler P, Williams R, Baum H, Burroughs A, Vergani D. Cross-reactivity to lactobacillus Delbrueckii/human pyruvate complex-E2 characterizes primary biliary cirrhosis. Hepatology 2000; 32: 300A.

  148. Abdulkarim AS, Petrovic LM, Kim WR, Angulo P, Lloyd RV, Lindor KD. Primary biliary cirrhosis: An infectious disease caused by Chlamydia pneumoniae? J Hepatol 2004; 40: 380-4.

  149. Fussey SP, Lindsay JG, Fuller C, Perham RN, Dale S, James OF, Bassendine MF, Yeaman SJ. Autoantibodies in primary biliary cirrhosis: Analysis of reactivity. Hepatology 1991; 13: 467-74.

  150. Takeuchi M, Hamana K, Hiraishi A. Proposal of the genus Sphingomonas sensu strictu and three new genera, Sphingobium, Novosphingobium and Sphingopyxis, on the basis of phylogenetic and chemotaxonomic analyses. Int J Syst Evol Microbiol 2001; 51: 1405-17.

  151. Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, Leung PS, Kenny TP, Van De Water J, Nantz MH, Kurth MJ, Gershwin ME. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 2003; 38: 1250-57.

  152. Long SA, Quan C, Van de Water J, Nantz MH, Kurth MJ, Barsky D, Colvin ME, Lam KS, Coppel RL, Ansari A, Gershwin ME. Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: Connecting xenobiotics with primary biliary cirrhosis. J Immunol 2001; 167: 2956-63.

  153. Kaplan MM. Novosphingobium aromaticivorans: a potential initiator of primary biliary cirrhosis. Am J Gastroenterol 2004; 99: 2147-9.

  154. Mason AL, Xu L, Guo L, Munoz S, Jaspan JB, Bryer-Ash M, Cao Y, Sander DM, Shoenfeld Y, Ahmed A, Van de Water J, Gershwin ME, Garry RF. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 1998; 351: 1620-4.

  155. Xu L, Sakalian M, Shen Z, Loss G, Neuberger J, Mason A. Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis. Hepatology 2004; 39: 151-6.

  156. Medzhitov R, Janeway Jr. CA, How does the immune system distinguish self from nonself? Semin Immunol 2000; 12: 257-344.

  157. Rose NR. Viral damage or “molecular mimicry”-lacing the blame in myocarditis. Nat Med 2000; 6: 631-632.

  158. Powell JJ, Van De Water J, Gershwin ME. Evidence for the role of environmental agents in the initiation or progression of autoimmune conditions. Environ Health Perspect 1999; 107: 667-672.

  159. Rao T, Richardson B. Environmentally induced autoimmune diseases: potential mechanisms. Environ Health Perspect 1999; 107: 737-742.

  160. Kammer AR, van der Burg SH, Grabscheid B, Hunziker IP, Kwappenberg KM, Reichen J, Melief CJ, Cerny A. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med 1999; 190: 169-176.

  161. Tanaka A, Lindor K, Ansari A, Gershwin ME. Fetal microchimerisms in the mother: immunologic implications. Liver Transpl 2000; 6: 138-43.

  162. Corpechot C, Barbu V, Chazouilleres O, Poupon R. Fetal microchimerism in primary biliary cirrhosis. J Hepatol 2000; 33: 696-700.

  163. Fanning PA, Jonsson JR, Clouston AD, Edwards-Smith C, Balderson GA, Macdonald GA, Crawford DH, Kerlin P, Powell LW, Powell EE. Detection of male DNA in the liver of female patients with primary biliary cirrhosis. Hepatol 2000; 33: 690-5.

  164. Rubbia-Brandt L, Philippeaux MM, Chavez S, Mentha G, Borisch B, Hadengue A. FISH for Y chromosome in women with primary biliary cirrhosis: lack of evidence for leukocyte microchimerism. Hepatology 1999; 30: 821-2.

  165. Tanaka A, Lindor K, Gish R, Batts K, Shiratori Y, Omata M, Nelson JL, Ansari A, Coppel R, Newsome M, Gershwin ME. Fetal microchimerism alone does not contribute to the induction of primary biliary cirrhosis. Hepatology 1999; 30: 833-8.

  166. Howel D, Fischbacher CM, Bhopal RS, Gray J, Metcalf JV, James OF. An exploratory population-based case-control study of primary biliary cirrhosis. Hepatology 2000; 31: 1055-60.

  167. Jones DE, James OF, Bassendine MF. Primary biliary cirrhosis: clinical and associated autoimmune features and natural history. Clin Liver Dis 1998; 2: 265-82.

  168. Powell FC, Schroeter AL, Dickson ER. Primary biliary cirrhosis and the CREST syndrome: a report of 22 cases. Q J Med 1987; 62: 75-82.




2020     |     www.medigraphic.com